BIO 2008: India and Innovation

Missed Madame Piramal’s presentation, unfortunately, while running back and forth between segments of the building and the show floor. The message behind speakers at the session on Indian Biotech was clear: don’t think “low cost,” think innovation. BMS alumnus Rashmi Barbhaiya used the Nano, India’s new model car, as a metaphor. He and Ramesh Adige, director of communications at Ranbaxy, offered a glimpse of the Indian biotech landscape. For YouTube-quality video, taken by yours truly: Rashmi Barbhaiya, CEO, Advinus Therapeutics on Biotech in India Ramesh Adige, Ranbaxy Labs, on India's Biotech Efforts AMS
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


  • <p>One could say that supply chain security is the most critical issue facing drug manufacturers today—and perhaps facing our healthcare system as well. The supply chain is at the heart of healthcare’s greatest problems—drug counterfeiting and adulteration, shortages of key medicines, and of course escalating medical costs. Without security of supply, none of these challenges can be addressed. <a href="">ccie</a> | <a href="">cisco ccie</a> | <a href="">ccie training</a> | <a href="">itil v3 certification</a> | <a href="">itil v3 exam</a> | <a href="">itil v3 foundation certification</a> | <a href="">ccent</a> | <a href="">ccent practice exam</a> | </p>


RSS feed for comments on this page | RSS feed for all comments